Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maplirpacept plus glofitamab after obinutuzumab in relapsed or refractory diffuse large B-cell lymphoma
jRCT2071230043Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of maplirpacept, glofitamab and obinutuzumab in diffuse large B-cell lymphoma (DLBCL), sponsored by Pfizer. Started Aug 2023; status: recruiting.
02
Drugs
maplirpaceptglofitamabobinutuzumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2071230043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230043.